Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward F Fritsch

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Nature Medicine|March 27, 2026
Publisher Correction: Clinical development of cancer vaccinesJohn B Haanen, Ton N M Schumacher, Jonathan C Kagan, et al.
Neuro-Oncology|September 6, 2014
Immunotherapy advances for glioblastomaDavid A Reardon, Gordon Freeman, Catherine Wu, et al.
Blood|June 4, 2014
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemiaMohini Rajasagi, Sachet A Shukla, Edward F Fritsch, et al.
Cancer Immunology, Immunotherapy : CII|December 20, 2018
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppressionKathleen M Mahoney, Sachet A Shukla, Nikolaos Patsoukis, et al.
Oncoimmunology|March 26, 2019
Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastomaTanner M Johanns, Christopher A Miller, Connor J Liu, et al.
Blood|August 29, 2018
A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigensZhuting Hu, Annabelle J Anandappa, Jing Sun, et al.
Immunity|February 10, 2021
Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope predictionJennifer G Abelin, Dewi Harjanto, Matthew Malloy, et al.
Immunity|September 10, 2019
Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope PredictionJennifer G Abelin, Dewi Harjanto, Matthew Malloy, et al.
Nature|July 22, 2021
Phenotype, specificity and avidity of antitumour CD8<sup>+</sup> T cells in melanomaGiacomo Oliveira, Kari Stromhaug, Susan Klaeger, et al.
Nature|May 4, 2022
Landscape of helper and regulatory antitumour CD4<sup>+</sup> T cells in melanomaGiacomo Oliveira, Kari Stromhaug, Nicoletta Cieri, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Nature Medicine|March 27, 2026
Publisher Correction: Clinical development of cancer vaccinesJohn B Haanen, Ton N M Schumacher, Jonathan C Kagan, et al.
Neuro-Oncology|September 6, 2014
Immunotherapy advances for glioblastomaDavid A Reardon, Gordon Freeman, Catherine Wu, et al.
Blood|June 4, 2014
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemiaMohini Rajasagi, Sachet A Shukla, Edward F Fritsch, et al.
Cancer Immunology, Immunotherapy : CII|December 20, 2018
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppressionKathleen M Mahoney, Sachet A Shukla, Nikolaos Patsoukis, et al.
Oncoimmunology|March 26, 2019
Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastomaTanner M Johanns, Christopher A Miller, Connor J Liu, et al.
Blood|August 29, 2018
A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigensZhuting Hu, Annabelle J Anandappa, Jing Sun, et al.
Immunity|February 10, 2021
Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope predictionJennifer G Abelin, Dewi Harjanto, Matthew Malloy, et al.
Immunity|September 10, 2019
Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope PredictionJennifer G Abelin, Dewi Harjanto, Matthew Malloy, et al.
Nature|July 22, 2021
Phenotype, specificity and avidity of antitumour CD8<sup>+</sup> T cells in melanomaGiacomo Oliveira, Kari Stromhaug, Susan Klaeger, et al.
Nature|May 4, 2022
Landscape of helper and regulatory antitumour CD4<sup>+</sup> T cells in melanomaGiacomo Oliveira, Kari Stromhaug, Nicoletta Cieri, et al.
Pageof 3